RSK2 promotes melanoma cell proliferation and vemurafenib resistance via upregulating cyclin D1

RSK2 promotes melanoma cell proliferation and vemurafenib resistance via upregulating cyclin D1

BRAF inhibitors are commonly used in targeted therapies for melanoma patients harboring BRAFV600E mutant. Despite the benefit of vemurafenib therapy, acquired resistance during or after treatment remains a major obstacle in BRAFV600E mutant melanoma. Here we found that RSK2 is overexpressed in melan...

Full description

Bibliographic Details
Main Authors: Hai-Zhou Wu, Lan-Ya Li, Shi-Long Jiang, Yi-Zhi Li, Xiao-Mei Shi, Xin-Yuan Sun, Zhuo Li, Yan Cheng
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-09-01
Series:Frontiers in Pharmacology
Subjects:
melanoma
Rsk2
vemurafenib
cyclin D1
FoxO1
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2022.950571/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2022.950571/full

Similar Items